(177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer

The aim of this narrative review is to evaluate the current status of (177)Lu-PSMA (prostate specific membrane antigen) therapy for metastatic castration-resistant prostate cancer (mCRPC) in the light of the current literature. We also addressed patient preparation, therapy administration and side e...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanli, Yasemin, Simsek, Duygu Has, Sanli, Oner, Subramaniam, Rathan M., Kendi, Ayse Tuba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071500/
https://www.ncbi.nlm.nih.gov/pubmed/33921146
http://dx.doi.org/10.3390/biomedicines9040430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071500/
https://www.ncbi.nlm.nih.gov/pubmed/33921146
http://dx.doi.org/10.3390/biomedicines9040430

Ejemplares similares